A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Tarlatamab (Primary) ; Pembrolizumab
- Indications Carcinoma; Small cell lung cancer
- Focus Adverse reactions; First in man
- Acronyms DeLLphi 300
- Sponsors Amgen
- 20 Dec 2023 Planned End Date changed from 7 Apr 2025 to 21 Oct 2025.
- 20 Dec 2023 Planned primary completion date changed from 20 Oct 2024 to 22 Oct 2024.
- 31 Oct 2023 Status changed from recruiting to active, no longer recruiting, according to an Amgen media release.